Open AccessEnhanced CD3‐mediated T lymphocyte proliferation in patients with systemic lupus erythematosus
Author(s) -
Stekman Ivan L.,
Blasini Ana M.,
LeonPonte Matilde,
Baroja Miren L.,
Abadi Isaac,
Rodriguez Martin A.
Publication year - 1991
Publication title -
arthritis & rheumatism
Language(s) - English
Resource type - Journals
eISSN - 1529-0131
pISSN - 0004-3591
DOI - 10.1002/art.1780340411
Subject(s) - cd3 , interleukin 2 , immunology , endocrinology , lupus erythematosus , t lymphocyte , medicine , monoclonal antibody , lymphocyte , phorbol , receptor , biology , chemistry , antibody , immune system , signal transduction , protein kinase c , cd8 , biochemistry
Nonfractionated peripheral blood lymphocytes from patients with systemic lupus erythematosus (SLE) showed enhanced proliferative responses when stimulated via the CD3 pathway. In contrast, proliferative responses induced by phytohemagglutinin were diminished in SLE patients. Levels of CD3‐induced interleukin‐2 production and interleukin‐2 receptor expression were comparable with normal levels. Highly purified T cells also showed augmented CD3 responses, but only in the presence of phorbol myristate acetate or a combination of phorbol myristate acetate plus calcium ionophore A23187, and not with calcium ionophore alone. The data suggest integrity of the T cell receptor/CD3 pathway for T cell activation in patients with SLE, as examined in cultures stimulated with specific anti‐CD3 monoclonal antibodies rather than with multivalent lectins. An increased response via the CD3 complex could contribute to the autoimmune activity in human SLE.